No abstract available.
PUVA Therapy* ; Telangiectasis*

BACKGROUND: Psoriatic lesions have reduced water-holding capacity and show increased transepidermal water loss (TEWL). The effect of D-PUVA therapy, which combines topical calcipotriol and PUVA therapy, on epidermal barrier function has not yet been evaluated. OBJECTIVE: The purpose of this study was to verify the change of TEWL in lesional and normal skin according to D-PUVA therapy in psoriasis patients. METHODS: TEWL was measured consecutively by TEWAMETER TM210®, in 13 psoriasis patients who received D-PUVA therapy. Clinical grading was done according to psoriasis severity index (PSI). RESULTS: TEWL of psoriatic lesion decreased as D-PUVA continued. TEWL of normal-looking skin gradually increased, although the increase was trivial. Clinical grading of scale and in-filtration followed the pattern of PSI in the decrease of TEWL, while that of erythema did not. CONCLUSION: In psoriatic plaques, TEWL was decreased according to the improvement. In normal-looking skin, D-PUVA therapy caused only a little effect on TEWL.
Erythema ; Humans ; Psoriasis ; PUVA Therapy ; Skin ; Water*

Recent studies have demonstrated that the patients with psoriasis have various immune alternation in both humoral and cellular immunities. However the results of these are still controversial. These facts promoted us to analyze the immune cells (T cell, T subsets and B cell) by rosette method for these cells in peripheral blood of 15 patients with psoriasis. And we also analyzed the effects of photo- chemotherapy(PUVA) on these cells. The results were summerized as follows; 1. The mean values of T cell, T, T, cell and B cell in peripheral blood of the- patients with psoriasis before PUVA therapy were 56. 2+-5.7%, 35.1+-6.9%, 5. 5+l.4%, 11.6+4. 0% respectively, These results of immune cells showed signi- ficantly lower mean values when these were compaired with the mean values. of nomnal control group(T cell; 65. 2+-2.9%, TM cell; 45.8+-3.2%, T cell; 7.3+ 1.3% B cell; 16.2+2.4%), respectively (T cell, Tm Tg, p<0.01, B cell; p<0.05). 2. The mean values of T cell, T, T, cell and B cell in peripheral blood (countinue..)
Humans ; Immunity, Cellular ; Photochemotherapy* ; Psoriasis* ; PUVA Therapy

Pityriasis lichenoides chronica is characterized by unknown etiology, chronicity and by being essentially asymptomatic and refractory to therapy. Nine patients with pityriasis lichenoides chronica were treated with orally administrated 8-Methoxypsoralen and UVA irradiation(PUVA Therapy). After S-45 PUVA treatments, lesions were completely cleared.
Humans ; Methoxsalen ; Pityriasis Lichenoides* ; Pityriasis* ; PUVA Therapy*

BACKGROUND: Although treament with PUVA or etretinate is effective for psoriasis, both treatment regimens have limitation because of the risk of long-term toxicity. OBJECTIVE: The present study was performed to compare the clinical effects of PUVA and retinoid-PUVA. METHODS: Twenty five chronic plaque psoriasis patients with more than 20% involvement of the skin suface were included in this study. Sixteen patiens were treated with the PUVA therapy and nine patients were treated with retinoid-PUVA. RESULTS: the number of phototherapy and cumulative UVA doses of retinoid-PUVA were significantly smaller than those of PUVA therapy. CONCLUSION: Combining PUVA with etretinate in the tretment of psoriasis may lead to lowering of total number of PUVA treatments and the cumulative dosage and it may be possible to shorten the duration of using etretinate.
Acitretin ; Etretinate ; Humans ; Phototherapy ; Psoriasis* ; PUVA Therapy ; Skin

The pathogenesis of scleroderma has not been completely delineated, but it is suggested that increased collagen expression in fibroblast from sclerotic skin lesions may be an important factor contributing to collagen accumulation. PUVA therapy has been reported to be effective in the treatment of localized scleroderma. Its mechanism of action appears to be the stimulation of collagenase production by dermal fibroblasts. We report a case of localized scleroderma improved with systemic PUVA therapy.
Collagen ; Collagenases ; Fibroblasts ; PUVA Therapy* ; Scleroderma, Localized* ; Skin

Cutaneous plasmacytosis is a rare disorder characterized by disseminated, macular, red-brown skin eruptions, which commonly occur on the trunk. Histologically, polyclonal lymphoplasmacytic infiltrates are sometimes shown to be associated with variable extracutaneous manifestations. Cutaneous plasmacytosis should be differentiated from primary cutaneous plasmacytoma, because both diseases are clinicopathological similar. Most cases of cutaneous plasmacytosis have been reported in Japanese literature. However, this case deals with a Korean female patient who was diagnosed with cutaneous plasmacytosis and subsequently received systemic PUVA therapy.
Asian Continental Ancestry Group ; Female ; Humans ; Plasmacytoma ; PUVA Therapy ; Skin

Lichen aureus is regarded as an uncommon variant of the pigmented purpuric dermatosis and resistant to treatment. Recently several authors reported the PUVA therapy to be effective in the pigmented purpuric dermatosis, but there was no report that the PUVA therapy was tried to the lichen aureus. We tried topical PUVA therapy on a 54-year-old male with bilateral lichen aureus. After 23 times of topical PUVA therapy, the lesion improved markedly. This report may provide a new method of treatment for lichen aureus.
Humans ; Lichens* ; Male ; Middle Aged ; PUVA Therapy* ; Skin Diseases

A lg year-old female patient with pityriasis lichenoides et varioliforrnis acuta (PLEVA) was been treated with PUVA, At first, she was treated with tetracycline for 8 weeks with improvement somewhat. But 2 months later, her skin lesions aggravated slowly. So, we tried to treated her with PUVA and then she was cleared completely. The initial dose of UVA was 5 J/cm The UVA dosage increased by 10g of the previous exposure and increased to the maximum dose, 15 J/cm The patient exposed to UVA R times per week. 12 times after the PUVA therapy, the skin lesions begin to improve and completely improved at 21 times of Pl.JVA therapy. She was followed up every week and there was no side effect except hyperpigrnentation till 24 months. The total dose during treatment is 210 J/cm.
Female ; Humans ; Photochemotherapy* ; Pityriasis Lichenoides* ; Pityriasis* ; PUVA Therapy ; Skin ; Tetracycline

BACKGROUND: The PUVA therapy of psoriasis is a very effective therapeutic modality that combines the action of light and drugs. Generally the conventional PUVA therapy based on patient's skin type is used in Korea. But there are many reported that conventional PUVA therapy is not suitable in several instances including the determination of oral 8-methoxypsoralen(8-MOP) dose, initial and incremental UVA dose and so on. OBJECTIVE: The purpose of this study is to establish a new protocol of PUVA therapy that is photomedically acceptable. METHOD: From 1997 to 2001, twenty psoriasis patients of moderate to severe grade who visited our clinic, were treated with PUVA therapy. Initial UVA dose was the same as MPD of each patient and proportion of weekly incremental UVA dose was 20% added to previous dose. All patients received PUVA therapy twice a week. The 8-MOP dose was determined by body surface area. RESULT: Total of 8 patients were skin type III, and 12 patients were skin type IV. The average of initial MPD in skin type III was 1.75J/cm2(0.5~2.5J/cm2) and skin type IV was 3.25J/cm2(2.5~4.5J/cm2). The average number of treatments to the end of therapy were 13.63(10~16) in skin type III, and 12.5(8~18) in skin type IV. The total cumulative UVA dose was 44.73J/cm2(30~68.2J/cm2) in skin type III, and 67.98J/cm2(31.6~109J/cm2) in skin type IV. CONCLUSION: The excellent effectiveness and safety of our new PUVA protocol have been demonstrated. We conclude that this PUVA protocol is a very effective, safe, and efficient method for the treatment of psoriatic patients.
Body Surface Area ; Humans ; Korea ; Methoxsalen ; Psoriasis* ; PUVA Therapy* ; Skin